Treatment for prostate cancer has long focused on targeting the activity of the AR [1–3], however prostate cancer is an heterogeneous disease where the underlying mechanisms for progression to castrate resistant prostate cancer are not clearly understood [4]. The gene discussed is AR; the disease is prostate carcinoma.